Skip to main content
Premium Trial:

Request an Annual Quote

Olink Bioscience, Molecular Devices, Millipore, IDBS

Premium
Olink Bioscience this week previewed its DuoLink reagent kit at the annual meeting of the American Association of Cancer Research in Los Angeles and the annual meeting of the European Society of Clinical Investigation in Uppsala, Sweden.
 
DuoLink, which is scheduled for commercial launch in the second quarter, comprises DNA-tagged antibodies and fluorescently labeled oligonucleotides and is based on the company’s in situ Proximity Ligation Assay.
 
The company said that in situ PLA can detect single molecular events such as protein interactions and modifications without the use of artificially stimulated or genetically modified cells. The method is applicable to the study of signaling pathways involved in tumorigenesis, “as well as a means of quantifying the response to anti-cancer drugs and other questions of interest in high-content screening applications,” the company said.
 

 
Molecular Devices, a division of MDS Analytical Technologies, released several new products at the Society for Biomolecular Sciences conference this week in Montreal. The first, a new aequorin option for its FLIPR Tetra fluorometric imaging plate reader, includes a new camera that can detect both fluorescence and aequorin luminescence. The addition also includes a new cell suspension option.  
 
The company said that the new aequorin option enables cell suspension assays, which minimizes cell preparation time and reduces assay costs.
 
The company also launched a live cell Neurotransmitter Transporter Uptake Assay Kit, which screens for live cell kinetic uptake of dopamine, norepinephrine, and serotonin.
 
This assay uses a masking dye to extinguish extracellular fluorescence. Molecular Devices said it exclusively licensed the masking dye technology from Bayer AG.
 

 
Millipore has added the human L-type calcium channel to its CardiacProfiler service for compound liability testing. The company said it has added the PrecisION hCav1.2 recombinant cell line, which “has been developed and validated to meet biophysical and pharmacological properties of the L-type calcium channel found in the human heart.”
 
The CardiacProfiler service offers compound profiling against the L-type calcium channel assessed either as a stand alone service or as part of a panel of other cardiac ion channels, including hERG, Nav1.5, KCNQ1/minK, Kv1.5, Kv4.3/KChIP1, and HCN4. 
 

 
IDBS has launched ActivityBase XE v7.0, which includes support for complex assay types, such as multiplexing and high-content screening, the company said.
 
ActivityBase XE includes new multiple curve fitting functionality and visualization tools and provides a "single environment for data capture, visualization, verification, quality control, and storage," the company said.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.